TB-500 is a synthetic thymosin beta-4 derivative with a development status of "preclinical". The Institute rates the strength of its published evidence as emerging. A synthetic version of a naturally occurring actin-binding peptide studied in models of tissue repair, cell migration, and cardiac injury.
Commercial availability of TB-500 continues to run ahead of its regulatory status. That is the recurring structural feature of this market: demand arrives when trial data is published, and supply arrives from channels that answer to nobody in particular.
The practical consequence for buyers is that a headline about promising results tends to be followed within weeks by a wave of new sellers, and the quality of that wave is not correlated with the quality of the science that prompted it.
The Institute has independently tested 7 TB-500 samples from 6 companies. 100% met their label claims on purity and content. Measured purity ranged from 97.4% to 99.7%, averaging 98.3%. Every specimen is published in full, including the laboratory that ran it.
The Peptide Institute is an independent research institute. We do not sell products, we do not accept vendor sponsorship, and we publish results that reflect badly on companies as readily as results that do not.
